CN115989229A - 5-氮杂-4’-硫代-2’-脱氧胞苷的多晶型物 - Google Patents

5-氮杂-4’-硫代-2’-脱氧胞苷的多晶型物 Download PDF

Info

Publication number
CN115989229A
CN115989229A CN202180052138.4A CN202180052138A CN115989229A CN 115989229 A CN115989229 A CN 115989229A CN 202180052138 A CN202180052138 A CN 202180052138A CN 115989229 A CN115989229 A CN 115989229A
Authority
CN
China
Prior art keywords
crystalline polymorph
cancer
aza
days
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180052138.4A
Other languages
English (en)
Chinese (zh)
Inventor
M·J·苏托
郑斗瑛
李振洙
赵显龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pinot Bio Co ltd
Southern Research Institute
Original Assignee
Pinot Bio Co ltd
Southern Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pinot Bio Co ltd, Southern Research Institute filed Critical Pinot Bio Co ltd
Publication of CN115989229A publication Critical patent/CN115989229A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180052138.4A 2020-07-23 2021-07-23 5-氮杂-4’-硫代-2’-脱氧胞苷的多晶型物 Pending CN115989229A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063055754P 2020-07-23 2020-07-23
US63/055,754 2020-07-23
PCT/US2021/043021 WO2022020747A1 (en) 2020-07-23 2021-07-23 Polymorophs of 5-aza-4'-thio-2-deoxycytidine

Publications (1)

Publication Number Publication Date
CN115989229A true CN115989229A (zh) 2023-04-18

Family

ID=79687860

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180052138.4A Pending CN115989229A (zh) 2020-07-23 2021-07-23 5-氮杂-4’-硫代-2’-脱氧胞苷的多晶型物

Country Status (10)

Country Link
US (1) US11447472B2 (cg-RX-API-DMAC7.html)
EP (1) EP4185583A4 (cg-RX-API-DMAC7.html)
JP (1) JP7679452B2 (cg-RX-API-DMAC7.html)
KR (1) KR102866823B1 (cg-RX-API-DMAC7.html)
CN (1) CN115989229A (cg-RX-API-DMAC7.html)
AU (1) AU2021314329A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001236A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186696A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023000979A (cg-RX-API-DMAC7.html)
WO (1) WO2022020747A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230123277A1 (en) * 2021-10-15 2023-04-20 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease and thalassemia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101014246A (zh) * 2004-07-13 2007-08-08 苏伯俭股份有限公司 地西他滨多晶型物的组合物和制剂及其使用方法
WO2019152459A1 (en) * 2018-02-01 2019-08-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stereoselective synthesis and process for the manufacturing of 2'-deoxynucleosides
WO2019204637A1 (en) * 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020322A (en) 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
US5591722A (en) * 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
CN103951583B (zh) 2006-12-06 2016-01-06 科内图斯医药公司 一种抑制剂的结晶形式
DK3782612T3 (da) 2008-05-15 2024-01-15 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
WO2011109012A1 (en) 2010-03-02 2011-09-09 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
US20110218170A1 (en) 2010-03-02 2011-09-08 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
CN106687139A (zh) 2014-07-14 2017-05-17 吉利德科学公司 用于治疗癌症的组合
US20160312261A1 (en) 2015-04-24 2016-10-27 Plasmia Biotech, S.L. Enzymatic production of cytosinic nucleoside analogues
US20190240210A1 (en) 2016-10-17 2019-08-08 Daiichi Sankyo Company, Limited Treatment Method by Combined Use of MDM2 Inhibitor and DNA Methyltransferase Inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101014246A (zh) * 2004-07-13 2007-08-08 苏伯俭股份有限公司 地西他滨多晶型物的组合物和制剂及其使用方法
WO2019152459A1 (en) * 2018-02-01 2019-08-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stereoselective synthesis and process for the manufacturing of 2'-deoxynucleosides
WO2019204637A1 (en) * 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
THOTTASSERY, JV ET AL.: "Novel DNA methyltransferase‑1 (DNMT1) depleting anticancer nucleosides, 4′-thio-2′-deoxycytidine and 5-aza-4′-thio-2′-deoxycytidine", CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 74, no. 2, 8 June 2014 (2014-06-08), pages 291 - 302, XP093163393, DOI: 10.1007/s00280-014-2503-z *
TIWARI, KN ET AL.: "Synthesis and Anti-cancer Activity of Some Novel 5-Azacytosine Nucleosides", NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, vol. 22, no. 12, 31 December 2003 (2003-12-31), pages 2161 - 2170, XP055221323, DOI: 10.1081/NCN-120026872 *

Also Published As

Publication number Publication date
WO2022020747A8 (en) 2023-02-16
BR112023001236A2 (pt) 2023-04-04
US11447472B2 (en) 2022-09-20
US20220024903A1 (en) 2022-01-27
EP4185583A4 (en) 2024-10-30
EP4185583A1 (en) 2023-05-31
AU2021314329A1 (en) 2023-02-23
AU2021314329A8 (en) 2023-03-09
WO2022020747A1 (en) 2022-01-27
JP2023535724A (ja) 2023-08-21
MX2023000979A (es) 2023-04-20
KR102866823B1 (ko) 2025-09-30
JP7679452B2 (ja) 2025-05-19
CA3186696A1 (en) 2022-01-27
KR20230061354A (ko) 2023-05-08

Similar Documents

Publication Publication Date Title
CN110636884B (zh) 新结晶形式
US20210169877A1 (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
WO2020165646A1 (en) Crystalline forms of an rsk inhibitor
US20080015350A1 (en) Crystalline and amorphous forms of beta-L-2'-deoxythymidine
AU2019256465A1 (en) 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
JP7679452B2 (ja) 5-アザ-4’-チオ-2’-デオキシシチジンの多形
JP2022522395A (ja) 選択的エストロゲン受容体分解剤の新規な塩
EP3414225B1 (en) Crystalline modifications of n-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine hydrochloride and n-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine salts
KR20230113186A (ko) 5-아자-4'-티오-2'-데옥시사이티딘을 함유하는 경구용 제형 및 이의 제조방법
CN113173881B (zh) 羟尼酮的晶型及其制备方法和用途
TW201833112A (zh) 化合物的晶型
JP5788175B2 (ja) 安定なエルサミトルシン塩製剤
HK40085219A (en) Novel crystalline forms
HK40078032A (en) Solid state crystalline forms of a selective potassium channel modulator
HK40016048A (en) Novel crystalline forms
HK40016048B (en) Novel crystalline forms
HK1184163A (en) Amorphous form of beta- l-2'-deoxythymidine
CN103467415A (zh) 一种卡巴他赛结晶形式及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20230418